Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which have recently emerged as a potential game-changer. However, several questions remain to be addressed, including the identificatio...
Main Author: | Alessandro Rizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/13/3912 |
Similar Items
-
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
by: Francesca Arezzo, et al.
Published: (2023-09-01) -
Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
by: Francesca Arezzo, et al.
Published: (2024-01-01) -
How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
by: Brigida Anna Maiorano, et al.
Published: (2022-04-01) -
Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status
by: Kiyoka Sawada, et al.
Published: (2023-04-01) -
An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
by: Michele Bartoletti, et al.
Published: (2022-07-01)